医疗诊断公司Veracyte(VCYT)在周一盘后大幅下跌7.45%,引发了市场的广泛关注。根据公司公布的2024年第四季度财报数据,Veracyte虽然营收稍高于预期,但调整后每股收益却大幅低于分析师consensus预期,这可能是主要导致股价大跌的原因。
具体来看,Veracyte2024年第四季度调整后每股收益为0.06美元,低于分析师0.11美元的一致预期,下滑幅度高达45.45%。尽管每股收益相比去年同期的0.05美元实现了20%的增长,但显然未达到投资者预期,收益数据低于预期引发了市场对公司前景的担忧。
不过,Veracyte2024年第四季度营收118.6百万美元则超出分析师consensus预期的116.765百万美元,同比增长20.78%。营收增长抵消了部分盈利不佳带来的负面影响,但显然还是无法满足市场对公司业绩的整体期望,因此造成股价在盘后大幅下挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.